Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Evinova will operate as a separate health-tech business within AstraZeneca
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The company has raised US$4.5 million in funding for its AI operating system
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Subscribe To Our Newsletter & Stay Updated
